Capsule Summary Slidesets

Share

Program Content

Activities

LA CAB + RPV in People Without Viral Suppression
LA CAB + RPV in People Without HIV Viral Suppression at Baseline at Ward 86: Wk 48 Results
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 06, 2024

CARES: LA CAB + RPV in Africa
CARES: Long-Acting CAB + RPV in Sub-Saharan Africa
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 06, 2024

IMPAACT 2010 Hypertension
IMPAACT 2010: Post hoc Analysis of Hypertension in Pregnant Women Initiating DTG + FTC/TAF, DTG + FTC/TDF, or EFV/FTC/TDF
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 07, 2024

The SLIM LIVER: Semaglutide in HIV
The SLIM LIVER: Effects of Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People Living With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 07, 2024

IMPAACT 2017/MOCHA
IMPAACT 2017/MOCHA Cohort 2: Wk 24 Safety, Efficacy, and PK Data After Switching to LA CAB + RPV in Adolescents Living With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 08, 2024

Doxy-PEP
Incidence of Bacterial STI Cases After Adoption of Doxy-PEP in Transgender Women and in Men Who Have Sex With Men
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 08, 2024

INSIGHT BIC in TB
INSIGHT: Wk 24 Efficacy, Safety, and PK of BIC/FTC/TAF in Adults Living With HIV and Tuberculosis Receiving Rifampicin
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 08, 2024

Phase II Trial of ISL and LEN
Phase II Trial of Oral Weekly Islatravir (ISL) + Lenacapavir (LEN) in Virologically Suppressed People Living With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 08, 2024

ACTG A5359 LATITUDE
ACTG A5359 LATITUDE: Long-Acting CAB + RPV vs Oral ART in People Living With HIV With Adherence Challenges
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 08, 2024

Expires: March 07, 2025

Resistance to 2nd Gen INSTIs
Emergence of Resistance Mutations in People Living With HIV Receiving Second-Generation INSTIs
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 11, 2024

Expires: March 10, 2025

REPRIEVE Mechanistic Substudy
REPRIEVE: Mechanistic Substudy of Effects of Pitavastatin on Plaque in People Living With HIV and Low-Moderate ASCVD Risk
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2024

Expires: March 11, 2025

Provided by

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare